Highlights

Strong financial performance with revenue exceeding pre-pandemic levels

• Group revenue up 8%, driven by increase in client activity; revenue up 5% on pre-pandemic levels
• Material improvement in Group adjusted EBITDA margin to 16.1% (FY21: 14.2%; FY20: 17.5%)
• Group adjusted earnings per share (‘EPS’) increased 65% to 22.6p (FY21: 13.7p; FY20: 24.0p)
• Reduced the leverage ratio to 3.9x (FY21: 5.1x), below pre-pandemic levels (FY20: 4.3x)
• Proposed dividend re-instatement at 3.00 pence per share (FY21: nil)

Continued delivery against key priorities

• Dealing with the pandemic effectively, caring for around 85 000 COVID-19 inpatients since its onset
• Progressing towards pre-pandemic profitability, with FY22 performance in line with improved outlook
• Executing on Group strategy, positioning the Company as an integrated healthcare partner
• Further improving value to all stakeholders

Positive FY23 outlook

• Expect increased client activity to drive further revenue growth, margin expansion and improved earnings
• Improving profitability and strong operating cash flows expected to support continued deleveraging
• Executing on opportunities to grow across the continuum of care
• Enhancing digital healthcare solutions for clients and healthcare professionals
• Investing in ESG initiatives to deliver on sustainable development strategy and achieve 2030 targets